VAXX - Vaxxinity, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Dallas,
United States
Type: Equity
VAXX price evolution
VAXX
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $0.41 | $0.4 | $0.41 | $0.52 |
| Inventory | ||||
| Total current assets | $33.23 | $46.4 | $59.7 | $73.43 |
| Long term investments | ||||
| Property, plant & equipment | $11.08 | $11.1 | $11.66 | $12.1 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $44.31 | $57.5 | $71.37 | $85.53 |
| Current liabilities | ||||
| Accounts payable | $1.78 | $3 | $1.89 | $3.03 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $17.61 | $21.6 | $23.78 | $26.47 |
| Long term debt | $13.26 | $12 | $12.34 | $12.69 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $30.9 | $33.8 | $36.35 | $39.4 |
| Shareholders' equity | ||||
| Retained earnings | -$361.64 | -$350.2 | -$337.1 | -$323.12 |
| Other shareholder equity | $0.01 | -$0.02 | -$0.05 | |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $0.41 | $0.41 | $0.39 | $0.39 |
| Inventory | ||||
| Total current assets | $33.23 | $93.89 | $154.13 | $35.67 |
| Long term investments | ||||
| Property, plant & equipment | $11.08 | $12.51 | $12.17 | $12.16 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $44.31 | $106.4 | $166.67 | $50.14 |
| Current liabilities | ||||
| Accounts payable | $1.78 | $5.29 | $3.19 | $1.02 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $17.61 | $30.94 | $27.49 | $37.22 |
| Long term debt | $13.26 | $13.04 | $10.32 | $10.7 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $30.9 | $44.22 | $38.05 | $75.04 |
| Shareholders' equity | ||||
| Retained earnings | -$361.64 | -$304.7 | -$229.48 | -$92.31 |
| Other shareholder equity | $0.01 | -$0.2 | ||
| Total shareholder equity | ||||
| (in millions $) | 29 Oct 2022 | 29 Jul 2022 | 30 Apr 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.07 | |||
| Cost of revenue | ||||
| Gross Profit | -$1.87 | |||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $19.77 | $17.22 | $18.16 | $123.2 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $0.52 | -$0.03 | -$0.1 | -$0.85 |
| Net income | ||||
| Net income | -$19.25 | -$17.25 | -$18.26 | -$137.18 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 | |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.07 | $0.56 | ||
| Cost of revenue | ||||
| Gross Profit | -$1.87 | $0.51 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $123.2 | $32.79 | $13.66 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.06 | |||
| Interest expense | -$0.85 | -$1.26 | -$0.47 | |
| Net income | ||||
| Net income | -$137.18 | -$39.96 | -$14.22 | |
| Income (for common shares) | ||||
| (in millions $) | 29 Oct 2022 | 29 Jul 2022 | 30 Apr 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$81.6 | -$1.25 | -$0.71 | -$1.32 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$0.06 | $0.02 | $0.01 | $196.17 |
| Effect of exchange rate | $0 | |||
| Change in cash and equivalents | -$123.11 | -$31.28 | -$20.21 | $113.86 |
| (in millions $) | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 | |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$1.32 | -$1.48 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $196.17 | $66.11 | $11.14 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $113.86 | $30.72 | -$1.13 | |
News
Fundamentals
| Market cap | $16.86M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 126.75M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$191.94M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.09 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.51 |
|---|---|
| ROA | -296.77% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.89 |
| Quick ratio | N/A |